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Contemporary investigations of mechanisms of resistance to platinides showed the key role of copper 
metabolism in cancer patients and proposed possible methods to attenuate the resistance by modulation of 
copper transporting mechanisms. In this vein, investigation of ceruloplasmin (Cp) levels – the main copper-
containing protein in blood, in experiments with tumor-containing animals upon cytostatics administration 
is topical and has great importance. the concentration of Cp was measured in the serum of tumor-bearing 
rats with ordinary (t8) and resistant to cisplatin (t8*) Guerin’s carcinoma upon administration of cisplatin 
and quadruple bonding dirhenium(III) compound dichlorotetra-μ-isobutyratodirhenium(ІІІ) (I) in different 
medicamental forms. It was shown that development of tumor in t8 group led to increasing of concentration 
of Cp in 3.7 times and in T8* group – more than in 8 times in comparison to control, confirming the essential 
role of Cp in the formation of resistance phenomenon. administration of cisplatin together with I led to effec-
tive inhibition of tumor in groups with t8 and t8*, indicating decreased resistance in the group t8*. Greater 
reduction of Cp levels was observed in the groups with t8* upon administration of the rhenium-plati num 
antitumor system, than in groups with t8, that underlines the importance of further investigations of the 
dirhenium(III) compounds in the resistance to cytostatics cancer models. Some mechanisms concerning the 
regulation of copper homeostasis and properties of nano-composites are discussed.
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C eruloplasmin (Cp) is a copper-containing protein that includes 40-70% of the whole plasma copper. It possesses the enzymatic 
activity as ferroxidase and takes part in oxidizing of 
bivalent iron. Cp belongs to proteins of acute phase 
and serves as a marker of inflammation [1].
Changing of Cp concentrations in blood was 
shown under different diseases. The reducing of Cp 
level was noticed under Wilson’s, Menson’s disea-
ses, copper deficiencies and aceruloplasmia [2]. 
Also, the Cp level is changing under cancer develop-
ment: concentration of Cp in blood was increased 
under oncological diseases of different etiologies and 
increased Cp level was also found in the tissues of 
onco-patients [3].
Contemporary knowledge about Cp functions 
in cancerogenesis includes its role as a prognostic 
marker of some types of cancer [4]; as an adipokine 
which is overexpressed in adipose tissue of obese 
subjects [5]; as a substance that promotes tumor pro-
gressions through influence on the glycolytic process 
in cancer cells [6].
It is well-known that resistance to platinides, 
especially to cisplatin (cPt), is a negative phenome-
non in the oncological practice and includes some 
complicated mechanisms, among which blockade 
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of the transport of platinides is considered to be the 
most ultimate. The expression of the human cop-
per transporter 1 (hCtr1), which transports also 
platinides, was found to be significantly reduced in 
cisplatin-resistant cancer cells. Moreover, one of the 
recently found tools to overcome cPt resistance was 
to introduce cPt together with copper - chelating 
agents [7-9].
In our previous works, the anticancer and an-
tioxidant properties of cluster rhenium(III) com-
pounds which were administered to tumor-bearing 
animals separately, with cPt, (Re – Pt system), in 
liposomal forms and in the forms of solid lipid na-
noparticles in the model of ordinary (T8) and re-
sistant to cPt (T8*) Guerin’s carcinoma was shown 
[10-12, 17]. But the concentration of Cp in these 
works was not investigated. Thus, the aim of the 
work was to investigate the influence of the introduc-
tion of cPt and a cluster rhenium(III) compound in 
the form of nanoliposomes and solid lipid nanopar-
ticles on the concentration of Cp in the blood of tu-
mor-bearing rats under development of T8 and T8*.
materials and methods
In our research, we studied the cluster com-
pound dichlorotetra-μ-isobutyratodirhenium(ІІІ) 
Re2(i-C3H7COO)4Cl2 – (i) synthesized in the 
Ukrainian State University of Chemical Technolo-
gy, Dnipro [13]. Nanoliposome [i] nl forms of i and 
the Re-Pt system with 4:1 ratio of the components 
inside lipid [i+cPt (4:1)] nl, [i+cPt (4:1)] np were pre-
pared ibid according to [14]. The experimental part 
was described in detail in [11, 17, 18].
All animal experiments were performed in ac-
cordance with the rules of the European Convention 
for the protection of vertebrate animals used for ex-
perimental and other scientific purposes (Strasbourg, 
1986). Rats without tumor were control group (con-
trol, No 1). Tumor growth was modeled by trans-
plantation of 20% suspension of T8 or T8* to healthy 
rats (groups T8, No 2 and T8*, No 5 respectively).
A single intraperitoneal injection of cPt in 
solution (sl) or nanoliposomal (nl) forms at a dose 
1.75 µmol/kg was performed on the 9th day after 
tumors transplantation, groups: T8+cPt sl, No 3; 
T8*+cPt sl, No 6; T8+cPt nl, No 4; T8*+cPt nl, No 7. 
The Re-Pt antitumor system was introduced with 
separately introductions of the components when 
cPt was introduced in the same mode and quanti-
ties as in groups 3, 6 and 4, 7 and on the 3rd day 
after tumor transplantation i was administrated ten 
times in liposomes in the dose of 7 µmol/kg, groups: 
T8+cPt+[i] nl, No 8; T8*+cPt+[i] nl, No 10; and in 
the form of mixed nanoliposomes and nanoparticles 
(np), where both cytostatics were inside lipid nano-
capsules, in the same quantities and rations, groups: 
T8+[i+cPt(4:1)] nl, No 9; T8+[i+cPt(4:1)] np, No 11; 
T8*+[i+cPt (4:1)] nl, No 12; T8*+[i+cPt(4:1)] np, 
No 13. Quantity of experimental animals in each 
group was 6-8.
Experimental animals were decapitated under 
chloroform anesthesia on the 21st day. Blood was 
collected in test tubes. The serum was obtained 
by natu ral plasma coagulation. The content of the 
Cp was investigated in the serum using the Ravin 
method and the standard reagent set (Private Joint-
Stock Company Reagent, Ukraine). The degree of 
reduction of oxidative stress in plasma of experimen-
tal animals was evaluated as the ratio of the con-
centration of MDA in plasma of experimental ani-
mals to the concentration of MDA in plasma of rats 
with Guerin’s carcinoma without any administration 
(ordinary or, respectively, resistant) [11, 17]. The re-
sults were statistically processed using the Student’s 
t-test. Differences in values were considered statisti-
cally significant at P ≤ 0.05.
results and discussion
Development of ordinary Guerin’s carcinoma 
T8 led to increasing of concentration of Cp in 3.7 
times in comparison to control (groups No 2 and 
No 1), Table 1.
At the same time, Cp concentration in serum of 
T8* – bearing rats increased in 8.5 times in compari-
son to control. Thus, development of a cPt-resistant 
tumor T8* led to increasing of Cp concentration in 
2.3 times more intensively in comparison to ordinary 
tumor T8. These findings may support the upper 
cited works about essential role of Cp in the forma-
tion of resistance phenomenon in cancer cells [7-9].
Introduction of cPt solutions to tumor-bearing 
rats showed different directions of changing of Cp 
levels in T8 and T8* groups of animals: if introduc-
tion of cPt to T8 group led to increasing of Cp level 
on 22.9% in comparison to T8 group, the same in-
troduction to T8* group led to decreasing of Cp on 
27.0% in comparison to T8* group of animals. To 
our knowledge, such an essential difference in eleva-
tion or dropping of Cp levels as a reply to cisplatin 
solution introductions is first demonstrated.
Introductions of liposomes loaded with cPt led 
to higher efficacy of tumor inhibition in T8* group 
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t a b l e  1. the concentration of Cp in serum, tumors inhibition and reducing of plasma mDa concentration 
in comparison to t8 and t8* groups under cPt introduction




of the group Cp, mg/l
Tumors inhibition, 
% [10, 17]
Reducing of plasma MDA 
concentration, % [10, 17]
1 Control 30.8 ± 1.5 – –
2 T8 112.6 ± 3.7* – –
3 T8+cPt sl   138.4 ± 6.9*,# 72.0 ± 3.6 35.5 ± 1.6
4 T8+cPt nl     261.4 ± 12.9*,# 65,0 ± 3.3 55.9 ± 3.1
5 T8*   261.4 ± 18.5* – –
6 T8*+cPt sl   190.8 ± 9.5*,## 36.0 ± 1.8 32.4 ± 1.6
7 T8*+cPt nl  260.5 ± 13.0* 52.3 ± 2.6 79.2 ± 3.6
and to higher levels of Cp in both T8 and T8* groups 
(up to 261 mg/l). These differences in tumor inhibi-
tion in our experiments with free and encapsulated 
cPt in T8* group of animals coincide by numerous 
examples of successful application of liposomal for-
mulations in attempts to overcome resistance [15]. 
So high Cp levels in groups’ No 4 and No 7 has no 
explanation at the moment and require more detailed 
investigations. But differences in Cp levels between 
group’s No 3 – No 4 and No 6 – No 7, i.e. in the 
influence of free cisplatin and liposomal cisplatin 
introductions on Cp concentrations may take place 
due to that known fact that liposomes have another 
transporting properties and mechanism of interac-
tion with cancer cells than free forms of medicines. 
In fact, liposomal forms of drugs enter the cyto-
plasm, bypassing active import.
Reducing of tumors always was accompanied 
by the decreasing of oxidative stress, especially un-
der application of the liposomal drugs [12, 17], that 
is also confirmed by data presented in Table 1. In 
both kinds of tumors, introductions of liposomal 
forms of cisplatin led to more essential decreasing 
of the intensity of peroxide oxidation of lipids (POL).
Introduction of the Re-Pt system in liposomal 
forms (groups 8, 9, 10) led to very effective inhi-
bition of T8 (Table 2) that was also shown earlier 
[11, 17].
Effective inhibition of tumor in groups with T8 
(No 8, No 9, No 10) and T8* (No 11, No 12, No 13 
that is an example of resistance overcoming) coin-
cided with relatively low concentrations of Cp (68.5–
204.0% to control) and (70.0–135.0% to control) re-
spectively. Also, the decreasing of POL intensity in 
blood of experimental animals is observed. 
Comparing data of Tables 1 and 2 we may con-
clude that introducing of the rhenium compound i in 
any form together with cisplatin led to the lowering 
of Cp together with effective inhibition of the tumors 
as ordinary, as resistant to cisplatin.
Especially interesting is to compare groups 
No 3 and No 8; No 6 and No 11. In all these ex-
t a b l e  2. the concentration of Cp in serum, inhibition of tumors and reducing of plasma mDa concentra-
tion in comparison to t8 and t8* after re-Pt system introduction




of the group Cp, mg/l
Tumors inhibition, 
% [11, 17]
Reducing of plasma MDA 
concentration, % [11, 17]
8 T8+[i] nl+cPt sl  93.5 ± 4.6*,# 96.9 ± 4.8 81.8 ± 4.0
9 T8+[i+cPt(4:1)] nl    71.0 ± 3.5*,## 97.8 ± 4.9 85.8 ± 4.0
10 T8+[i+cPt(4:1)] np    51.8 ± 2.6*,## 96.2 ± 4.8 76.0 ± 3.7
11 T8*+[i] nl+cPt sl 72.3 ± 4.1* 98.0 ± 4.9 52.2 ± 2.1
12 T8*+[i+cPt(4:1)] nl    52.3 ± 2.6*,## 70.8 ± 3.5 80.7 ± 3.5
13 T8*+[i+cPt(4:1)] np  56.1 ± 1.3## 46.5 ± 0.3 23.1 ± 1.0
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perimental groups the equal quantities of cisplatin in 
solution were introduced to tumor-bearing animals, 
but in groups No 8 and No 11 it was introduced af-
ter pretreatment with the rhenium compound in the 
liposomal form [i] nl. Efficacy of tumor inhibition 
was higher in these groups, and the Cp level was 
lower in 2.5–3 times in comparison to groups, where 
[i] nl was absent (No 3 and No 6).
Thus, according to the aim of the work, we 
have shown that development of a cPt-resistant tu-
mor T8* led to increasing of Cp concentration in 2.3 
times more intensively in comparison to ordinary 
tumor T8; introduction of cPt solutions to tumor-
bearing rats showed different directions of changing 
of Cp levels in T8 and T8* groups of animals; in-
troductions of liposomes loaded with cPt led to 
higher levels of Cp in both T8 and T8* groups in 
comparison to groups with free cPt introductions; 
introducing of the rhenium compound i in any form 
together with cisplatin led to the lowering of Cp in 
comparison to groups with cPt introductions.
If also to compare the average Cp level between 
groups of tumor-bearing rats shown in Table 3, it is 
evident that in the groups No 8, No 9 and No 10 
there were level reduction in average by 36.0% in 
comparison to T8 (Table 1, group No 2).
Greater reduction of Cp levels was observed in 
the groups No 11, No 12 and No 13 with T8*, where 
the Re-Pt system was introduced. There was a reduc-
tion of Cp levels in average on 77.0% in comparison 
to T8* (Table 1, group No 5). The comparison with 
appropriate groups where i was introduced together 
with cisplatin, also showed the larger reduction of the 
Cp concentration in groups with T8* than in groups 
with T8. It means that i influence on the copper ho-
meostasis of both types of tumors, but in somehow 
different manner that underlines the importance of 
following investigations of the dirhenium(III) com-
pounds in the cancer models with resistance to cy-
tostatics.
Recent findings revealed that hCtr1 regulates 
intracellular copper homeostasis, which, in turn, 
controls hCtr1 expression via a homeostatic feedback 
loop [7, 9]. The copper-lowering agents increased 
the expression of hCtr1, subsequently resensitizing 
tumor cells to platinum therapy. Does the rhenium 
compound i play somehow the role of the copper-
lowering agent in these experiments? We have no 
any supplying facts for this now. But if so, the hy-
pothesis that resistance to platinum therapy can be 
reversed through the use of a copper-lowering agent 
as a rhenium compound like i is very promising. But 
we know, that mechanism of platinum compounds 
transport are multifactorial and any stage of the 
mechanisms underlying cisplatin transport (both 
import and export) and retention in the tumor cells 
are important determinants and may be affected by i.
Introductions of nano-liposomes and solid lipid 
nanoparticles, loaded with cisplatin and i, was effec-
tive as in tumor-decreasing, as in POL inhibition and 
also was accompanied by low Cp levels. These nano-
particles also come to the cancer cell bypassing ac-
tive import, fusing with the cell membranes of can-
cer cells [12]. The efficacy of such “nanobins” was 
explained by us by the existence of the equilibrium 
inside a nanoparticle [14] between i, phosphatidyl-
choline and cisplatin that is shown on the Figure.
As it was shown for the dirhenium (III) com-
pound with cis-dicarboxylate structure [14], phos-
phatidylcholine moieties from the lipid shell sub-
stituted axial positions and cisplatin may substitute 
carboxylic groups. In the case with i, this substitu-
tion may take place with the formation of several 
adducts mono-, di-, three- and even four-substituted 
products. Such equilibrium inside a liposome con-
sisting from i, phosphatidylcholine and cisplatin (or 
t a b l e  3. Decreasing of the ceruloplasmin concentration in serum after re-Pt system introduction in com-
parison to t8 and t8* groups without or with cPt applying
Number 
of the group Characteristic of the group To T8, %
To T8+cPt in 
appropriate form, %
8 T8+[i] nl+cPt sl 17.0 ± 2.4 32.4 ± 3.3
9 T8+[i+cPt(4:1)] nl 37.0 ± 5.4 85.5 ± 2.7
10 T8+[i+cPt(4:1)] np 54.0 ± 2.8 –
11 T8*+[i] nl+cPt sl 72.4 ± 2.2 62.1 ± 4.3
12 T8*+[i+cPt(4:1)] nl 80.0 ± 1.4 79.9 ± 3.1
13 T8*+[i+cPt(4:1)] np 78.5 ± 3.0 –
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hydrolyzed cisplatin) gives to the inner complex ad-
ditional chemical potential that facilitates interaction 
with DNA and results in synergistic or additive ef-
fect on DNA adducts formation [14].
In this work, we showed that cisplatin drug 
resistance might be overcome by the simultaneous 
introduction of a rhenium cluster compound and 
cisplatin in different nano-forms. Successful tu-
mor growth inhibition was followed by decreasing 
of Cp level and POL intensity in plasma that opens 
new aspects of the influence of rhenium quadruple 
bonding compounds on the copper homeostasis of 
tumor-bearing animals. We have demonstrated that 
this type of resistance is highly bound with the level 
of Cp that shows possible intervention procedures. In 
light of the complexity of сPt drug resistance, to en-
hance the overall outcome in cancer chemotherapy, it 
is imperative that other resistance mechanisms have 
to be addressed as well.
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the reaction I with cisplatin and phosphatidylcholine which possibly may pass in the liposome
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Сучасні дослідження механізмів резистент-
ності до платинидів показали вирішальну роль 
метаболізму міді в онкопацієнтів та обґрунту-
вали методи подолання резистентності шляхом 
модуляції транспортних механізмів міді. Вихо-
дячи з цього, визначення рівня церулоплазміну 
(Ср) – основного мідьвмісного протеїну крові в 
екс периментах з тваринами-пухлиноносіями за 
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введення цитостатиків є важливим і актуаль-
ним. Концентрацію Ср вимірювали в сироват-
ці щурів-пухлиноносіїв зі звичайною (Т8) і ре-
зистентною до цисплатину (Т8*) карциномою 
Герена за введення цисплатину і сполуки ди-
ренію (ІІІ) з почверним зв’язком дихлоротетра-
μ-ізобутиратодиренію (ІІІ) (i) у різних лікар-
ських формах. Показано, що розвиток пухлин 
у тварин групи Т8 супроводжувався підвищен-
ням концентрації Ср у 3,7 раза, а у тварин групи 
T8* – більше ніж у 8 разів порівняно з інтактни-
ми тваринами, що підтверджує істотну роль Ср 
у формуванні явища резистентності. Введення 
цисплатину разом із i призводило до ефективно-
го інгібування пухлинного росту в групах з Т8 
і Т8*, що для групи Т8* є прикладом подолання 
резистентності до цисплатину. Зниження кон-
центрації Cp у групах тварин T8*, що отриму-
вали реній-платин, було істотнішим, ніж у гру-
пах T8, що підкреслює важливість подальших 
досліджень диренієвих (III) сполук у моделях 
резистентного до цитостатиків канцерогенезу. 
Обговорюються деякі механізми регулювання 
гомеостазу міді та властивостей нанокомпози-
тів.
К л ю ч о в і  с л о в а: церулоплазмін, клас-
терна сполука ренію(III), карцинома Герена, ре-
зистентність до цисплатину.
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